Iron, ferritin, hepatitis B surface and core antigens in the livers of chinese patients with hepatocellular carcinoma

hepatitis b virus core promoter mutations in patients with chronic hepatitis b and hepatocellular carcinoma in bucharest, romania

conclusions genotype d was the main genotype detected in romanian patients with chronic hbv infection. genotype d presented both bcp and pc mutations more frequently. results we detected two hbv genotypes; a (8.1%) and d (60.5%), and a mixture of genotypes a and d (31.4%) (p < 0.001). basal core promoter (bcp) a1762t/g1764a and precore (pc) g1896a mutations were detected in these romanian patie...

Hepatocellular carcinoma in children with hepatitis B surface antigen.

This study discusses four children of hepatocellular carcinoma (HCC) who were asymptomatic HBsAg carriers or had HBsAg-positive chronic hepatitis for 3 to 11 years before the occurrence of the carcinoma. Three of these four patients were positive for anti-HBe at 3 to 5 years before the diagnosis of hepatocellular carcinoma. Autopsy findings disclosed liver cirrhosis in all the four patients. To...

Hepatitis B Virus Core Promoter Mutations in Patients With Chronic Hepatitis B and Hepatocellular Carcinoma in Bucharest, Romania

BACKGROUND Accurate and personalized molecular virological diagnosis of hepatitis B virus (HBV) infection is crucial for individualized selection of patients for antiviral therapy in Romania. OBJECTIVES We aimed to investigate HBV mutations in Romanian patients with chronic HBV infection, also to match HBV genotypes with HBV mutations identified and clinical outcomes. PATIENTS AND METHODS T...

Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B

Expression of S and pre s2 Hepatitis B Surface Antigens in Mammalian Cos-7 Cell Line

Hepatitis B virus (HBV) is a serious global health problem. The development of a safe and effective vaccinewould help infection prevention. Previous hepatitis B vaccine production involved the isolation of the noninfectious particle from chronic HBV carriers. DNA recombinant technology has been used for vaccineproduction without having been contaminated with blood-born infectious ag...